This systematic review and meta-analysis, including 52,607 patients, demonstrated the different benefits of SGLT2 inhibitors in CV outcomes, including HHF, CV death, all-cause mortality, MACE and myocardial infarction, except ischemic stroke. Here, SLC5A2 is linked to myocardial infarction.